FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2092045389> ?p ?o ?g. }

• W2092045389 endingPage "458.e3" @default.
• W2092045389 startingPage "448" @default.
• W2092045389 abstract "Background Sublingual immunotherapy (SLIT) has become established in Europe, and its efficacy is being evaluated in the United States. The doses used for SLIT in Europe today are difficult to evaluate, because each manufacturer expresses the potency of its extracts differently. Objectives To compare in vitro European SLIT maintenance solutions against US licensed standardized allergenic extract concentrates and to determine the monthly SLIT doses delivered expressed in bioequivalent allergy units ([B]AU). Methods We studied Dermatophagoides pteronyssinus, timothy grass pollen, cat (hair) and short ragweed pollen allergen extracts. The SLIT maintenance solutions of 4 leading European manufacturers and standardized concentrate extracts of 3 US manufacturers were analyzed with the following assays: protein content, relative potency (immunoglobulin E [IgE]-binding enzyme-linked immunosorbent assay [ELISA] inhibition) and major allergen content. The relative monthly allergen dose in (B)AU was calculated for each recommended SLIT schedule. Results Relative potency was approximately 10 times higher for US concentrate standardized extracts—which are meant to be diluted—than for European SLIT maintenance solutions of D pteronyssinus and timothy grass pollen. For cat (hair) and short ragweed pollen, the difference was less. Measurements of relative potency and major allergen content correlated well. In our assays, European mite extracts contain a very low quantity of Der p 2 compared with US mites. Conclusion Recommended SLIT doses in Europe vary widely among the manufacturers, but are consistently lower (Eur1) or higher (Eur4) over all four allergens tested. SLIT efficacy probably depends on additional factors apart from the exact dose. SLIT dose finding studies should be done for each product. Sublingual immunotherapy (SLIT) has become established in Europe, and its efficacy is being evaluated in the United States. The doses used for SLIT in Europe today are difficult to evaluate, because each manufacturer expresses the potency of its extracts differently. To compare in vitro European SLIT maintenance solutions against US licensed standardized allergenic extract concentrates and to determine the monthly SLIT doses delivered expressed in bioequivalent allergy units ([B]AU). We studied Dermatophagoides pteronyssinus, timothy grass pollen, cat (hair) and short ragweed pollen allergen extracts. The SLIT maintenance solutions of 4 leading European manufacturers and standardized concentrate extracts of 3 US manufacturers were analyzed with the following assays: protein content, relative potency (immunoglobulin E [IgE]-binding enzyme-linked immunosorbent assay [ELISA] inhibition) and major allergen content. The relative monthly allergen dose in (B)AU was calculated for each recommended SLIT schedule. Relative potency was approximately 10 times higher for US concentrate standardized extracts—which are meant to be diluted—than for European SLIT maintenance solutions of D pteronyssinus and timothy grass pollen. For cat (hair) and short ragweed pollen, the difference was less. Measurements of relative potency and major allergen content correlated well. In our assays, European mite extracts contain a very low quantity of Der p 2 compared with US mites. Recommended SLIT doses in Europe vary widely among the manufacturers, but are consistently lower (Eur1) or higher (Eur4) over all four allergens tested. SLIT efficacy probably depends on additional factors apart from the exact dose. SLIT dose finding studies should be done for each product." @default.
• W2092045389 created "2016-06-24" @default.
• W2092045389 creator A5038251079 @default.
• W2092045389 creator A5043885964 @default.
• W2092045389 creator A5044383560 @default.
• W2092045389 creator A5046101163 @default.
• W2092045389 creator A5050531180 @default.
• W2092045389 creator A5075738351 @default.
• W2092045389 creator A5088465992 @default.
• W2092045389 date "2011-11-01" @default.
• W2092045389 modified "2023-09-29" @default.
• W2092045389 title "Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units" @default.
• W2092045389 cites W1486867751 @default.
• W2092045389 cites W1539224844 @default.
• W2092045389 cites W1599242518 @default.
• W2092045389 cites W1965377999 @default.
• W2092045389 cites W1975510539 @default.
• W2092045389 cites W1981529848 @default.
• W2092045389 cites W1984780114 @default.
• W2092045389 cites W1990684266 @default.
• W2092045389 cites W1996037171 @default.
• W2092045389 cites W2007572138 @default.
• W2092045389 cites W2016063789 @default.
• W2092045389 cites W2018309112 @default.
• W2092045389 cites W2022429437 @default.
• W2092045389 cites W2028280773 @default.
• W2092045389 cites W2032199331 @default.
• W2092045389 cites W2046710953 @default.
• W2092045389 cites W2088465681 @default.
• W2092045389 cites W2089792148 @default.
• W2092045389 cites W2092202984 @default.
• W2092045389 cites W2094041238 @default.
• W2092045389 cites W2096210343 @default.
• W2092045389 cites W2098913651 @default.
• W2092045389 cites W2107383821 @default.
• W2092045389 cites W2107470605 @default.
• W2092045389 cites W2112554764 @default.
• W2092045389 cites W2119547091 @default.
• W2092045389 cites W2125803815 @default.
• W2092045389 cites W2126816655 @default.
• W2092045389 cites W2132844265 @default.
• W2092045389 cites W2134264508 @default.
• W2092045389 cites W2158341249 @default.
• W2092045389 cites W2164132449 @default.
• W2092045389 cites W2165648644 @default.
• W2092045389 cites W2170079873 @default.
• W2092045389 doi "https://doi.org/10.1016/j.anai.2011.07.001" @default.
• W2092045389 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22018618" @default.
• W2092045389 hasPublicationYear "2011" @default.
• W2092045389 type Work @default.
• W2092045389 sameAs 2092045389 @default.
• W2092045389 citedByCount "43" @default.
• W2092045389 countsByYear W20920453892012 @default.
• W2092045389 countsByYear W20920453892013 @default.
• W2092045389 countsByYear W20920453892014 @default.
• W2092045389 countsByYear W20920453892015 @default.
• W2092045389 countsByYear W20920453892016 @default.
• W2092045389 countsByYear W20920453892017 @default.
• W2092045389 countsByYear W20920453892018 @default.
• W2092045389 countsByYear W20920453892019 @default.
• W2092045389 countsByYear W20920453892020 @default.
• W2092045389 countsByYear W20920453892021 @default.
• W2092045389 countsByYear W20920453892022 @default.
• W2092045389 countsByYear W20920453892023 @default.
• W2092045389 crossrefType "journal-article" @default.
• W2092045389 hasAuthorship W2092045389A5038251079 @default.
• W2092045389 hasAuthorship W2092045389A5043885964 @default.
• W2092045389 hasAuthorship W2092045389A5044383560 @default.
• W2092045389 hasAuthorship W2092045389A5046101163 @default.
• W2092045389 hasAuthorship W2092045389A5050531180 @default.
• W2092045389 hasAuthorship W2092045389A5075738351 @default.
• W2092045389 hasAuthorship W2092045389A5088465992 @default.
• W2092045389 hasConcept C141105273 @default.
• W2092045389 hasConcept C159654299 @default.
• W2092045389 hasConcept C181389837 @default.
• W2092045389 hasConcept C185592680 @default.
• W2092045389 hasConcept C199215989 @default.
• W2092045389 hasConcept C202751555 @default.
• W2092045389 hasConcept C203014093 @default.
• W2092045389 hasConcept C207480886 @default.
• W2092045389 hasConcept C2777037608 @default.
• W2092045389 hasConcept C2779350572 @default.
• W2092045389 hasConcept C2779787640 @default.
• W2092045389 hasConcept C2780510475 @default.
• W2092045389 hasConcept C2780931586 @default.
• W2092045389 hasConcept C33070731 @default.
• W2092045389 hasConcept C42404028 @default.
• W2092045389 hasConcept C54355233 @default.
• W2092045389 hasConcept C55493867 @default.
• W2092045389 hasConcept C57992300 @default.
• W2092045389 hasConcept C71924100 @default.
• W2092045389 hasConcept C86803240 @default.
• W2092045389 hasConcept C98274493 @default.
• W2092045389 hasConceptScore W2092045389C141105273 @default.
• W2092045389 hasConceptScore W2092045389C159654299 @default.
• W2092045389 hasConceptScore W2092045389C181389837 @default.
• W2092045389 hasConceptScore W2092045389C185592680 @default.
• W2092045389 hasConceptScore W2092045389C199215989 @default.

• next